Molecular Cancer Research Genome w/Abstract AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ganguli, G.
Right arrow Articles by Wasylyk, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganguli, G.
Right arrow Articles by Wasylyk, B.
Related Collections
Right arrow Cellular Pathobiology
Right arrow Cellular Pathobiology: Cancer Genes and Genomics
Molecular Cancer Research 1:1027-1035 (2003)
© 2003 American Association for Cancer Research

Subject Review

p53-Independent Functions of MDM21

Gitali Ganguli1 and Bohdan Wasylyk1

1 Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch cedex, France

Requests for reprints: B. Wasylyk, CNRS/INSERM/ULP, 1 Rue Laurent Fries, BP 10142, 67404 Illkirch cedex, France. Phone: 33-3-88-65-34-11; Fax: 33-3-88-65-32-01. E-mail: boh{at}igbmc.u-strasbg.fr

Abstract

The tumor suppressor p53 is inactivated by overexpression of MDM2 in about 10% of human tumors. However, p53 is inactivated by other mechanisms in the majority of tumors, raising the possibility that MDM2 may be irrelevant to transformation in most cases. However, MDM2 has been reported to have p53-independent functions, in cell cycle control, differentiation, cell fate determination, DNA repair, basal transcription, and other processes. Furthermore, MDM2 appears to contribute to the transformed phenotype in the absence of wild-type p53. Nevertheless, the number of studies is still limited, and the evidence in some cases does not unequivocally show that the functions are p53 independent. We will discuss the circuits of regulation involving MDM2 that do not directly concern p53. Hopefully, future work will consolidate our understanding of the p53-independent pathological functions of MDM2 and will lead to useful therapeutic interventions that target the majority of tumors.




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
A. Bouska, T. Lushnikova, S. Plaza, and C. M. Eischen
Mdm2 Promotes Genetic Instability and Transformation Independent of p53
Mol. Cell. Biol., August 1, 2008; 28(15): 4862 - 4874.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Maguire, P. C. Nield, T. Devling, R. E. Jenkins, B. K. Park, R. Polanski, N. Vlatkovic, and M. T. Boyd
MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination
Cancer Res., May 1, 2008; 68(9): 3232 - 3242.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. Malmlof, G. Paajarvi, J. Hogberg, and U. Stenius
Mdm2 as a Sensitive and Mechanistically Informative Marker for Genotoxicity Induced by Benzo[a]pyrene and Dibenzo[a,l]pyrene
Toxicol. Sci., April 1, 2008; 102(2): 232 - 240.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Z. Matijasevic, H. A. Steinman, K. Hoover, and S. N. Jones
MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice
Mol. Cell. Biol., February 15, 2008; 28(4): 1265 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
P. D'Arcy, W. Maruwge, B. A. Ryan, and B. Brodin
The Oncoprotein SS18-SSX1 Promotes p53 Ubiquitination and Degradation by Enhancing HDM2 Stability
Mol. Cancer Res., January 1, 2008; 6(1): 127 - 138.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Wawrzynow, A. Zylicz, M. Wallace, T. Hupp, and M. Zylicz
MDM2 Chaperones the p53 Tumor Suppressor
J. Biol. Chem., November 9, 2007; 282(45): 32603 - 32612.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
J.-C. W. Marine, M. A. Dyer, and A. G. Jochemsen
MDMX: from bench to bedside
J. Cell Sci., February 1, 2007; 120(3): 371 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. M. Nelson, V. Bhaskaran, W. R. Foster, and L. D. Lehman-McKeeman
p53-Independent Induction of Rat Hepatic Mdm2 following Administration of Phenobarbital and Pregnenolone 16{alpha}-Carbonitrile
Toxicol. Sci., December 1, 2006; 94(2): 272 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. S. Dias, Y. Liu, A. Yau, L. Westrick, and S. C. Evans
Regulation of hdm2 by Stress-Induced hdm2alt1 in Tumor and Nontumorigenic Cell Lines Correlating with p53 Stability
Cancer Res., October 1, 2006; 66(19): 9467 - 9473.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Z. Zhang, D. L. Evers, J. F. McCarville, J.-C. Dantonel, S.-M. Huong, and E.-S. Huang
Evidence that the Human Cytomegalovirus IE2-86 Protein Binds mdm2 and Facilitates mdm2 Degradation.
J. Virol., April 1, 2006; 80(8): 3833 - 3843.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Menin, M. C. Scaini, G. L. De Salvo, M. Biscuola, M. Quaggio, G. Esposito, C. Belluco, M. Montagna, S. Agata, E. D'Andrea, et al.
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
J Natl Cancer Inst, February 15, 2006; 98(4): 285 - 288.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Toth, P. Nickson, L. L. Qin, and P. Erhardt
Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase
J. Biol. Chem., February 10, 2006; 281(6): 3679 - 3689.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
G. W. Yu, M. D. Allen, A. Andreeva, A. R. Fersht, and M. Bycroft
Solution structure of the C4 zinc finger domain of HDM2
Protein Sci., February 1, 2006; 15(2): 384 - 389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Giglio, F. Mancini, F. Gentiletti, G. Sparaco, L. Felicioni, F. Barassi, C. Martella, A. Prodosmo, S. Iacovelli, F. Buttitta, et al.
Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
Cancer Res., November 1, 2005; 65(21): 9687 - 9694.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Li, Z. Zhang, D. L. Hill, X. Chen, H. Wang, and R. Zhang
Genistein, a Dietary Isoflavone, Down-Regulates the MDM2 Oncogene at Both Transcriptional and Posttranslational Levels
Cancer Res., September 15, 2005; 65(18): 8200 - 8208.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Slack, Z. Chen, R. Tonelli, M. Pule, L. Hunt, A. Pession, and J. M. Shohet
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
PNAS, January 18, 2005; 102(3): 731 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Berger, R. L. Camp, K. A. DiVito, H. M. Kluger, R. Halaban, and D. L. Rimm
Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome
Cancer Res., December 1, 2004; 64(23): 8767 - 8772.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.